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NF-κBSepsis is the major cause of death in the intensive care unit (ICU). Numerous biomarkers have been studied to
identify the cause and severity of sepsis but these factors cannot differentiate between infectious and non-
infectious inﬂammatory response. MicroRNAs (miRNAs) are non-coding RNA transcripts that regulate the
expression of genes by repressing translation or degrading mRNA. Importantly, miRNAs can be released outside
cells and easily detectable in bodily ﬂuids such as blood, sweat, urine and breast milk. Numerous studies have
explored the idea of utilizing extracellular miRNAs as biomarkers for sepsis by proﬁling the dysregulation of
miRNAs in blood samples of sepsis patients. So far, miR-223, miR-146a and miR-150 have been identiﬁed to
havepromising prognostic and diagnostic value to sepsis. In addition, various intracellularmiRNAs have been im-
plicated to play critical roles in regulating the TLR-NF-κB pathway,which is awell-known inﬂammatory signaling
pathway involved in the process of sepsis. Here, we summarize the recent progress on the role of extracellular
and intracellular miRNAs in sepsis. Speciﬁcally, we discuss the possible role of circulating miRNA biomarkers
for the diagnosis of sepsis and how intracellular miRNAs regulate the inﬂammatory responses in sepsis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Sepsis is a medical condition characterized by a severe systemic in-
ﬂammatory response due to an infection [1]. At present, sepsis is the
leading cause of death among patients admitted to the intensive care
units (ICU) [1]. About 28.3% to 41% of all sepsis patients do not survive
because of multiple organ failure [2]. Indeed, sepsis starts with an initial
systemic inﬂammatory response (SIRS), followed by severe sepsis with
multiple organ dysfunction before progressing to septic shockwith per-
sistent hypotension [3]. Moreover, sepsis might be misdiagnosed as the
SIRS because the initial inﬂammatory response could also be caused by
non-infectious substances such as burns, trauma and acute pancreatitis
[4]. There is thus a critical need to developmore accurate biomarkers for
the diagnosis of sepsis.
Over the past decade, numerous studies have been conducted to iden-
tify biomarkers that are sufﬁcient to deﬁne the stage and severity of sepsis
and predict the best line of treatment. The major challenge is that these
studies cannot identify the cause of the systemic inﬂammatory response
between SIRS and sepsis. Currently, biomarkers such as C-reactive protein
(CRP), procalcitonin (PCT), Interlukin-6 (IL-6), sTREM-1, amongst
others are being studied for their potential to detect SIRS caused by an
infection. CRP, which is an acute phase protein found in the liver, is
known to help in the removal of pathogens during infection [5]. PCT, a
prohormone of calcitonin found in C-cells of the thyroid gland, areacology and Cell Biophysics,
rt Sabin Way, Cincinnati, OHreleased in huge quantities into the blood stream during infection [6].
sTREM-1 are triggering receptors expressed on myeloid cells-1 which
are released into plasma by phagocytes during bacterial or fungi infec-
tion [7]. These factors have potential to be an indicator of an infection-
induced inﬂammatory response but experimental data have revealed
they are also present during a non-infectious inﬂammatory response
[4].
MicroRNAs are endogenous non-coding RNA molecules of about
19–22 nucleotides that play a role in post-translational gene silencing
by inhibiting translation or by degrading mRNA [8]. It is generally ac-
knowledged that a single miRNA can globally regulate the transcription
of hundreds of genes to organize complex programs of gene expression
which affects the overall functioning of a cell [9]. Signiﬁcantly, changes
in miRNA expression have been implicated in various disease states
such as cardiovascular diseases, autoimmune diseases, neurodegenera-
tive diseases, liver diseases and inﬂammatory diseases [10]. Lawrie et al.
[11] were the ﬁrst to introduce the idea of miRNAs as potential
biomarkers for diseases when they compared serum miRNA levels of
B-cell lymphoma patients with healthy individuals. Subsequently,
many studies have been performed to characterize the expression of
various miRNAs both intracellularly and extracellularly, advocating the
potential role of miRNAs as biomarkers for sepsis. In this review, we
will summarize such progress and discuss some potential issues.
In addition, intracellular miRNAs have been implicated as power-
ful endogenous factors in regulating the inﬂammatory signaling cas-
cades during sepsis. Currently, Toll-like receptor (TLR)-mediated
signaling pathway is well recognized to be involved in the development
of septic shock [12]. In humans, ten functional types of toll-like recep-
tors (TLR1-10) have been identiﬁed thus far. TLR1, TLR2, TLR4, TLR5,
2156 K. Essandoh, G.-C. Fan / Biochimica et Biophysica Acta 1842 (2014) 2155–2162TLR6 are stimulated by various lipids and protein in microbial walls
while TLR7, TLR8 and TLR9 recognize intracellular microbial nucleic
acids because of their localization to the endoplasmic reticulum,
endolysosomes, lysosomes and endosomes [13]. TLR4 is believed to rec-
ognize bacterial lipopolysaccharide (LPS) while lipoteichoic acid and
peptidoglycans stimulate TLR2 [13]. Recently, numerous intracellular
miRNAs have been deﬁned to regulate TLR2/4-NF- B signaling cascades.
Therefore, in this review, we will also discuss how miRNAs affect the
inﬂammatory signaling pathways involved in sepsis.
2. Biogenesis and release of microRNAs
AprimarymiRNA transcript (pri-miRNAs) is usually formed through
transcription by RNA polymerase II in the nucleus as a long capped pre-
cursor miRNA or through maturation from introns [14]. The ribonucle-
ase (RNase) III Dorsha enzyme and the DiGeorge Syndrome Critical
Region 8 (DGCR8) protein form a microprocessor complex to process
the 70–100 nt premature miRNA (pre-miRNA) from the pri-miRNA
[15]. With the help of nuclear export transporter Exportin 5, the pre-
miRNA is exported into the cytoplasm [16]. At its terminal loop, the
pre-miRNA interacts with RNase III endonuclease Dicer protein and
the co-factor double-stranded transactivation-responsive RNA-binding
protein (TRBP) to process the ~22 nt miRNA duplex [16]. The miRNA
duplex is integrated into the RNA-induced silencing complex (RISC)
which comprises of an argonaute (Ago) protein and a glycine-
tryptophan repeat-containing protein of 182 kDa. (GW182) [17]. Previ-
ously, it was assumed that one strand at the 3′ end of themiRNA duplex
(commonly called the “passenger strand”) is released and degraded,
while the other strand (called “guide strand”) is remained in the RISC
complex [18]. However, it has been demonstrated that both strands
can be processed into mature miRNA and utilized for translational
repression [19]. Mature miRNAs processed from the 3′ end are desig-
nated with a 3p sufﬁx while miRNAs processed from the 5′end are
identiﬁed with a 5p sufﬁx [19]. The RISC complex is directed to a 3′
or 5′ untranslated region (UTR) of an mRNA where there is base
pairing with 2 to 8 nucleotides (called “seed sequence”) of the ma-
ture miRNA [20].
MicroRNAs have the ability to be released outside cells into plasma
and remain in circulation in a stable form [21]. Contrary to previous be-
lief, microRNAs are highly conserved over evolutionary periods and are
highly resistant to endogenous and exogenous RNase activity, acute pH
and temperature conditions [22,23]. These properties are achieved in
plasma due to the fact that miRNAs are conﬁned to membrane bound
vesicles like microvesicles and exosomes. Release of miRNAs through
microvesicles/exosomes is ATP and temperature dependent [23].
Microvesicles are typically about 100–1000 nm in size and are generat-
ed from directly outward budding of cell membrane [23]. Conversely,
exosomes are about 30–100 nm in size and are produced from
multivesicular bodies (MVBs) when the MVBs fuse with the cell mem-
brane and are exocytosized out of the cell [24]. The MVBs themselves
originate from vesicles in the lumen of endosomes, which collect
endocytic membrane proteins within the cell. Exosomes have been
found in various bodily ﬂuids such as plasma, urine, serum, breast
milk and saliva [24].
Although it happens very rarely, some miRNAs are released into
plasma during tissue damage or cell apoptosis as apoptotic bodies
[25]. In addition, it has also been found that argonaute 2 (Ago2) protein
and high-density lipoproteins may act as carriers for miRNAs [26,27].
Put together, the biogenesis and release of miRNAs are summarized in
Fig. 1.
3. Extracellular microRNAs as potential biomarkers in sepsis
Obviously, extracellularmiRNAs that exist in blood, sweat, urine and
breast milk can be quantiﬁed rapidly in a clinical setting, unlike micro-
bial cultures that are time consuming. Such property of extracellularmiRNAs drives many investigators to identify possible biomarkers for
the diagnosis of disease. In the ﬁeld of sepsis, a number of studies
have been conducted to proﬁle plasma miRNAs of septic patients.
Several miRNAs have stood out as potential diagnostic and prognostic
biomarkers of sepsis and are reviewed below (Table 1).3.1. miR-150
Recently, Vasilescu et al. [28] comparedmiRNAproﬁles of 12 healthy
individuals and 10 sepsis patients. The authors' analyses revealed that
levels of miR-150 were mostly dysregulated in the peripheral blood
leukocytes between the two groups. Signiﬁcantly, the reduction in
miR-150 in sepsis patients correlated well with the severity of the
disease which was determined by the Sepsis-related Organ Failure
(SOFA) score. Given that the SOFA score does not account for thepathol-
ogy involved in sepsis [29], they further analyzed the role of miR-150 in
the pathogenesis of sepsis, and observed that the decrease in miR-150
in sepsis patients correlated with the increase of pro-inﬂammatory
cytokine, IL-18 [28].
However, with a different set of subjects, Roderburg et al. [30]
analyzed serum levels of miR-150 in 223 critically ill patients (138 diag-
nosed with sepsis and 85 without sepsis) and 76 healthy individuals.
Results of their analyses revealed that there was only a minor decrease
in the levels of miR-150 in critically ill patients compared to healthy
individuals. They concluded that miR-150 was not a good diagnostic
tool for sepsis. Nonetheless, they observed that amongst critically ill pa-
tients, a high level of serummiR-150 correlatedwith survival in patients
with sepsis while a lower level of miR-150 signiﬁed a high chance of
organ dysfunction and mortality. They postulated that miR-150 might
have a role to play as a prognostic tool for sepsis. Albeit just a minor
decrease, the study by Roderburg et al. [30] was consistent with the
ﬁndings of Vasilescu et al. [28] as both studies observed a reduction in
miR-150 levels in sepsis patients.3.2. miR-223 and miR-146a
miR-223 and miR-146a represent two of the most researched
miRNAs in relation to their role in the pathogenesis of various diseases.
In the ﬁeld of sepsis, Wang et al. [31] have demonstrated that miR-223
and miR-146a are dysregulated in sepsis patients. These authors exam-
ined seven miRNAs related to inﬂammation and infection in 50 sepsis
patients, 30 SIRS patients and 20 healthy people. The seven miRNAs
they tested were miR-132, miR-146a, miR-155, miR-223, miR-15b,
miR-126 and let-7i. Using quantitative PCR, they reported that serum
levels of miR-146a and miR-223 were signiﬁcantly reduced in patients
suffering from sepsis compared to SIRS patients and the healthy individ-
uals. Importantly, therewere no signiﬁcant changes in levels ofmiR-223
in SIRS patients compared to the healthy individuals. Subsequently,
another study, using RT-PCR, examined the differential expression of
miR-146a in plasma samples of 14 non-sepsis SIRS patients and 14 sep-
sis patients. The investigators observed higher levels of serummiR-146a
in non-sepsis SIRS patients compared to sepsis patients [32]. Hence,
these studies suggest that miR-146a andmiR-223may be optimal diag-
nostic tools for sepsis. Recently, one study proﬁled serum miRNAs of
214 sepsis patients (117 survivors and 97 non-survivors), and found
thatmiR-223 levels were signiﬁcantly lower in non-surviving sepsis pa-
tients compared to surviving sepsis patients [33]. Accordingly, using a
global knockout mouse model, our lab has observed that the loss of
pre-miR-223 aggravated sepsis-induced myocardial dysfunction, in-
ﬂammatory response and mortality to a greater degree than wild-type
mice [34]. Thus, miR-223 may have the potential to be used as a prog-
nostic tool to determine the line of treatment according to the severity
of the disease, and lower levels of miR-223 may contribute to septic
death.
Fig. 1. Biogenesis and release of miRNAs. After the processing by Dorsha/DGCR8 in the nucleus and followed by Dicer in the cytoplasm, miRNA is either incorporated in the RISC complex
to target mRNA repression; packaged into microvesicular bodies to be released as exosomes; or exocytyzed out of the cell as microvesicles. MiRNAs are also released by apoptotic bodies
during cell apoptosis and tissue damage. In addition, miRNAs may bind to some proteins such as HDL and Ago2, and released outside cells.
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Recently, miR-4772 family [miR-4772-3p, miR-4772-5p, miR-4772-
5p-iso (an isomiR of miR-4772-5p) has been shown to have prognostic
and diagnostic value to sepsis. Ma et al. [35] utilized Linear Discriminant
Analysis (LDA) for blood samples of 23 sepsis patients with conﬁrmed
bacterial infection, 22 SIRS patients and 21 healthy individuals. Firstly,
they RNA-sequenced 4 blood samples from each group, and demon-
strated that miR-4772-5p-iso was signiﬁcantly increased in the sepsis
group but could not distinguish between the SIRS and control groups.Table 1
Differential expression of miRNAs in various blood specimens of sepsis patients.
Specimen Study Sample Size Main ﬁnd
Blood
leukocytes
10 sepsis patients
12 healthy individuals
miR-15
miR-48
Serum 138 sepsis patients
85 ICU patients without sepsis
76 healthy individuals
miR-15
Serum 50 sepsis patients
30 SIRS patients
20 healthy individuals
miR-22
Serum 117 surviving sepsis patients
97 non-surviving sepsis patients
miR-22
miR-15
Plasma 14 non-sepsis SIRS patients
14 sepsis patients
miR-14
Blood leucocytes 23 sepsis patients
22 SIRS patients
21 healthy people
miR-47
miR-15
Plasma 78 surviving sepsis patients
64 non-surviving sepsis patients
miR-57
miR-29
Serum 17 ICU patients without sepsis
36 sepsis patients
miR-18
Blood leukocytes Sepsis patients and non-sepsis ICU patients miR-46
Serum 138 sepsis patients
85 ICU patients without sepsis
76 healthy individuals
miR-13MiR-4772-3p and miR-4772-5p were signiﬁcantly upregulated in the
sepsis group compared to the healthy individuals but could not distin-
guish between the sepsis and SIRS group. In vitro work also revealed
that miR-4772-5p-iso was upregulated in primary peripheral blood
monocytes after a 24 h challenge with speciﬁc TLR ligands, providing a
potential mechanistic explanation for their observed data in sepsis
patients. However, further analysis in the remaining blood samples
revealed that miR-150 was the only miRNA that could signiﬁcantly
distinguish between all three groups. Nevertheless, this study con-
ﬁrmed miR-150 as a potential biomarker for sepsis and showed that aings Reference
0, miR-342-5p
6, miR-182 in sepsis patients
[28]
0 amongst ICU patients with or without sepsis enhances survival [30]
3 and miR-146a in sepsis patients [31]
3, miR-16
a, miR-122, miR-193, miR-483-5p in surviving sepsis patients
[33]
6a in non-sepsis SIRS patients [32]
72 family
0 in sepsis patients
[35]
4-5p
7 in surviving sepsis patients
[37]
1b in sepsis patients [38]
6I in non-surviving sepsis patients [39]
3a correlated with severity of sepsis [40]
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of sepsis. Also, miR-4772-5p-iso has no murine homologue and it is
plausible that species-speciﬁc microRNAs are likely to represent more
speciﬁc biomarkers for human disease. In addition, miR-4772-5p-iso is
located in an intronic region of Interleukin 18 receptor accessory protein
gene (IL-18RAP), whichwas also increased during sepsis.More interest-
ingly, IL-18 itself has previously been reported to be upregulated during
sepsis [36] suggesting the co-regulation of IL-18RAP and IL-18.
3.4. Other miRNAs
In addition to the miRNAs outlined, the studies discussed above ob-
served the dysregulation of other miRNAs. For example, Vasilescu et al.
[28] found that levels of miR-486 and miR-182 were overexpressed
while miR-342-5p levels were reduced in the peripheral blood leuko-
cytes of sepsis patients compared to healthy individuals. Wang et al.
[33] observed that levels of miR-16 were increased while levels of
miR-15a, miR-122, miR-193 and miR-483-5p were decreased in the
sera of surviving sepsis patients compared to the non-surviving group.
Notably, other groups have also examined the differential expres-
sion of miRNAs in varying sets of subjects. For instance, Wang et al.
[37] used microarray screens to identify differentially expressed
serum miRNAs by comparing samples from 12 surviving and 12 non-
surviving sepsis patients. They observed that only levels of miR-297
and miR-574-5p were signiﬁcantly different between survivors and
non-survivors. In survivors, serummiR-297 levels were downregulated
while miR-574-5p levels were upregulated. These results were further
validated in additional serum samples of 66 survivors and 52 non-
survivors. When miRNA expression and sepsis stages were combined
with SOFA scores, they ﬁnally concluded that miR-574-5p had a better
predictive value and could potentially be used for the prognosis of
sepsis. Sun et al. [38] analyzed serum samples of control subjects (ICU
patients without sepsis) and sepsis patients for levels of circulating
miR-181b. They observed that serum miR-181b levels were reduced
by about 40% in sepsis patients compared to ICU patientswithout sepsis.
Recently, Li et al. [39] reported that levels of miR-466I in leukocytes
were higher in sepsis non-survivors than in sepsis survivors. There
was however no difference in serum levels of miR-466I between
survivors and non-survivors.
Furthermore, Tacke et al. [40] have found that miR-133a levels were
upregulated in sepsis patients and critically ill patients. In a subject pool
of 223 critically ill patients (138 with sepsis and 85 without sepsis) and
76 healthy individuals, the upregulation of miR-133a correlated with
sepsis severity, SOFA scores and bacterial infection markers CRP and
procalcitonin. In keeping with that observation, the authors proﬁled
serum miRNAs in septic mice induced by cecal ligation and puncture
(CLP) and observed the strongest change in expression in miR-133a
(16-fold) compared to miR-150, miR-155 and miR-125b. As demon-
strated by Tacke et al. [40], blood samples of septicmice can be screened
to determine the expression proﬁle of microRNAs. Using septic C57BL/6
mice induced by CLP, Wu et al. [41] proﬁled circulating miRNAs in
whole blood samples in the experimental sepsis mice. After microarray
analysis, levels of miR-16, miR-17, miR-20a, miR-20b, miR-26a, miR-
26b, miR-106a, miR-106b, miR-195 and miR-451 were higher in septic
mice compared to controls. Further analyses of these miRNAs in
TLR2−/−, TLR4−/− and NF-κB−/−mice revealed that there was no
signiﬁcant difference in expression levels compared to TLR2+/+,
TLR4+/+ and NF-κB +/+ mice after CLP. These results signify that
the expression of these ten miRNAs in blood is not dependent on
TLR2, TLR4 or NF-κB-dependent pathways.
Subsequently, the validity of miRNAs as biomarkers for sepsis has
been explored by Huang et al. [42] usingmicroarray expression proﬁles
and miRNA regulatory network analysis. The authors analyzed the ex-
pression proﬁles of miRNAs from various studies through validation
and prediction databases such as TarBase and HOCTAR, and measured
statistical signiﬁcance with the student t-test. The resulting miRNAswere further examined with pathway analysis, disease oncology analy-
sis, protein-protein interaction network (PIN) analysis and ROC curves
to ascertain their prognostic or diagnostic value to sepsis. In all, miR-
15a, miR-16, miR-122, miR-146a, miR-223, miR-499-5p and miR-150
were found to have diagnostic value to sepsis while miR-483-5p,
miR-574-5p and miR-193b were found to have prognostic value.
As reviewed above, a number of extracellular miRNAs have been
proposed to be candidate biomarkers for the diagnosis of sepsis. Given
the limited sample size they analyzed and the complex nature of sep-
sis/SIRS, it would be necessary to employ randomized prospective
large scale clinical trials in larger patient groups for evaluating the
accuracy of these proposed miRNA biomarkers in the future.
4. Intracellular microRNAs as regulators of inﬂammatory signaling
in sepsis
It is well recognized that the inﬂammatory response during sepsis is
mediated through the activation of TLRs and the downstream NF-κB
pathway in macrophages and monocytes [12]. After recognition of
LPS/endotoxin, the TLR recruits the adaptor protein myeloid differenti-
ation primary response gene 88 (MyD88) [43]. MyD88 recruits IL-1 re-
ceptor –associated kinases IRAK1, IRAK2 and IRAK4. The IRAK kinases
phosphorylate the tumor necrosis factor receptor-activated factor 6
(TRAF6) proteins, an ubiquitin protein ligase, which catalyzes the pro-
duction of a Lys63-linked polyubiquitin on the Iκ-B kinase subunit γ
[IKK- γ, also called the NF-κB modulator (NEMO)] and on the TRAF6
protein itself [44]. This interaction causes the recruitment of the
transforming growth factor-β (TGF-β)-activated kinase 1(TAK1)
which phosphorylates the β subunit of IKK complex and activates IKK
complex [44]. IKK complex is responsible for phosphorylating the
endogenous inhibitor of NF-κB (IκBa) in order to release the inhibitory
effects of IκBa on the NF-κB transcription factor [44]. The NF-κB tran-
scription factor contains the reticuloendotheliosis (Rel) proteins p50
and p65, which form heterodimers and are transferred to the nucleus
to activate the expression of inﬂammatory genes [45]. Alternatively, ac-
tivated TLR can recruit adaptor protein TIR-domain-containing adapter-
inducing interferon-B (TRIF) [46]. TRIF protein recruits receptor-
interacting protein-1 (RIP1) kinase which activates TAK1. Like the
myD88-dependent pathway, TAK1 phosphorylates IKK which leads to
the activation of NF-κB [46]. Unlike the myD88 pathway, the TRIF
pathway has not been studied extensively in sepsis.
Nowadays, it is very clear that the TLR-NF-κB inﬂammatory response
is involved in the process of sepsis. However, the use of anti-
inﬂammatory agents such as corticosteroids, antiendotoxin antibodies,
tumor necrosis factor (TNF) antagonists, interleukin-1–receptor antag-
onists have not been successful in treating sepsis [47]. This suggests
that other factorsmight be associatedwith sepsis. Indeed, recent studies
have shown that numerous intracellular miRNAs play critical roles in
the regulation of TLR signaling and NF-κB-mediated inﬂammatory
response (Fig. 2), as reviewed below.
4.1. Let-7i targets TLR4
The TLR4 receptor itself is predicted to be a target of the let-7i. Chen
et al. [48] reported that let-7i regulates TLR4 expression via post-
transcriptional suppression in cultured human biliary epithelial cells
(cholangiocytes). They observed that an infection of cultured human
cholangiocytes with Cryptosporidium parvum (a parasite that causes in-
testinal and biliary disease) results in decreased expression of primary
let-7i and mature let-7i in a MyD88/NF-κB-dependent manner. Signiﬁ-
cantly, the decreased let-7i expression is associated with C. parvum-
induced up-regulation of TLR4 in infected cells. Moreover, overexpres-
sion of a let-7i precursor in human cholangiocytes resulted in a
reduction of TLR4 protein content. These results indicate that let-7i reg-
ulates TLR4 expression in cholangiocytes and contributes to epithelial
immune responses against C. parvum infection. Furthermore, the data
Fig. 2. Negative regulationof TLR signaling bymiRNA. TLR4 is negatively regulated by let-7i andmiR-146b.MyD88 is negatively regulated bymiR-200b,miR-200c,miR-149 andmiR-203
and miR-146b. IRAK1 and TRAF6 can be targeted by miR-146 family. IKK-α is negatively regulated by miR-223, miR-15a and miR-16. IKK-β is negatively regulated by miR-199a. IkBα is
targeted by miR-126. TNFα is negatively regulated by miR-221, miR-579 and miR-125b.
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ways may be critical to host-cell regulatory responses to microbial
infection in general.4.2. miR-200 family, miR-149 and miR-203 affect MyD88
A recent study conducted by Wendlandt et al. [49] showed that the
miR-200 family (miR-200a, miR-200b, and miR-200c) could regulate
TLR4 signaling andNF-κB activation. UsingHEK293 cells and a luciferase
reporter assay, they observed that there was a dose-dependent repres-
sion of luciferase NF-κB activity when miR-200b and miR-200c mimics
were transfected while miR-200a had no effect. A luciferase assay
with reporter gene for the 3‘UTR of MyD88 showed decreased activity
when miR-200b and miR-200c were transfected. In contrast, when
miR-200b and miR-200c were transfected in a mutated 3′UTR of
myD88, there was no change in activity. In addition, all three miRNAs
in the miR-200 family had no effect on the 3‘UTR of TLR4, IRAK1 and
TRAF6. Together, this study indicates that MyD88 is a bona ﬁde target
for miR-200b and miR-200c.In addition to miR-200b and miR-200c, Xu et al. [50] showed that
miR-149 could negatively regulateMyD88protein levels. They observed
that when the RAW264.7 cells were stimulated with Myobacterium
bovis, there was an increase in levels of MyD88 and a decrease in miR-
149 levels.When a lentiviral vector expressingmiR-149was transfected
in RAW264.7 cells, therewas no change in levels of MyD88mRNA com-
pared to controls but there was a signiﬁcant decrease in myD88 protein
levels. Thus, miR-149 represses the translation of MyD88 but has no ef-
fect on the transcription. Similarly, Wei et al. [51] recently demonstrat-
ed that the overexpression of miR-203 in RAW264.7 cells signiﬁcantly
reduced protein rather than mRNA levels of MyD88.
4.3. miR-146 family negatively regulates IRAK1 and TRAF6
miR-146 family (miR-146a andmiR-146b) has been shown to nega-
tively modulate the translation of IRAK1and TRAF6. Tagonov et al. [52]
investigated the role of miR-146 family on the NF-κB-dependent im-
mune response and observed a signiﬁcant upregulation of miR-146,
miR-155 and miR-132 in THP-1 cells upon stimulation with LPS. miR-
146 was chosen for further analysis because it showed a rapid response
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gene for the 3′-UTR of IRAK1 and TRAF6, they found that bothmiR-146a
andmiR-146b caused a signiﬁcant reduction in luciferase activity when
transfected in HEK293 cells.
With more focus on miR-146b, Curtale et al. [53] showed that miR-
146b affects the TLR4 signaling pathway by targeting the TLR4 receptor,
myD88, IRAK1 and TRAF6. In luciferase assays of HEK293 cells, there
was decrease in activity of the reporter genes containing the 3′-UTR of
TLR4, myD88, IRAK1 and TRAF6 when miR-146b was transfected. To
conﬁrm speciﬁcity of targets, miR-146b was transfected into reporter
genes containing mutated regions of the 3′-UTR of TLR4, myD88,
IRAK1 and TRAF6 which resulted in no change in activity. In addition,
the authors observed an increase in miR-146b levels but not miR-146a
and miR155 when human monocyte cells were stimulated with IL-10.
4.4. miR-15, miR-16, miR-223 and miR-199a for the IKK complex and
miR-126 for Iκ-Bα
The IKK complex, consisting of IKK-α, IKK-β and IKK-γ (NEMO), is
essential for NF-κB activation. Using theMemorial Sloan-Kettering Can-
cer Center miRNA database, Li et al. [54] found that miR-15a, miR-16
and miR-223 had complementary sequences to the 3′UTR of the
IKK-α gene. There was a decrease in miR-15a, miR-16 and miR-223
levels and an increase in IKK-α levels when differentiation of human
monocytes was stimulated with granulocyte-macrophage colony-
stimulating factor (GM-CSF). The transfection of miR-15a, miR-16 and
miR-223 mimics into the human monocytes resulted in a decrease in
IKK-α protein levels. In the same vein, Chen et al. [55] employed the
PicTar algorithm, and found that the 3′-UTR of the IKK-β mRNA had
three complementary sequences for miR-199a. The co-transfection of
miR-199a with a luciferase construct containing the 3′UTR for IKK-β
into EOC ovarian cancer cells resulted in a decrease in luciferase activity.
A recent study by Feng et al. [56] has demonstrated that the 3′-UTR of
IκBα was complementary to the sequence of miR-126 through Micro-
Cosm Targets, Targetscan and PicTar. The transfection of a miR-126
mimic in HT29 cells resulted in a 57% reduction in IκBα protein levels.
4.5. miR-221, miR-579 and miR-125b target pro-inﬂammatory cytokine
TNFα
The productionof pro-inﬂammatory cytokines during the inﬂamma-
tory response can be directly targeted by miRNAs. El Gazzar and McCall
[57] utilized a computational target prediction algorithm to identify
miR-221, miR-579 and miR-125b as possible candidate miRNAs with
sequences complementary to the 3‘UTR of TNFα. They conﬁrmed the
repressive effect of miR-221, miR-579 and miR-125 on TNFα in LPS-
tolerant THP-1 cells. Transfection of miR-221 in THP-1 cells promoted
the degradation of TNFα mRNA levels while the transfection of
miR-579 and miR-125b resulted in a signiﬁcant reduction in TNFα
protein levels. The inhibitory effects of miR-125b on TNFαwere also re-
ported by Tili et al. [58]. The authors observed a decrease in luciferase
activity when miR-125b was co-transfected with the 3′UTR-TNFα
construct in HEK-293 cells. Accordingly, in LPS-treated RAW264.7Table 2
miRNAs regulate intracellular inﬂammatory response through interactions with various target
microRNA Targets
miR-21 pro-inﬂammatory protein PDCD
miR-33 Receptor-interacting protein 14
(RIP140)
miR-202-3p Ppargc1a
miR-182, miR-203, miR-211, miR-222, miR-199a-5p,
miR-29b
Activated Protein C (aPC)
miR-155 FADD and Ripk1macrophages, miR-125b was downregulated whereas TNFα was up-
regulated.
4.6. Other miRNAs affect the inﬂammatory signaling
PDCD4, a pro-inﬂammatory protein, is known to aid in the activation
of NF-κB [59]. miR-21 has been shown to regulate the expression of
PDCD4 by Sheedy et al. [60]. The authors transfected RAW264.7 cells
with antisense oligonucleotides for miR-21, which resulted in more
PDCD4 production after stimulation with LPS. Furthermore, the trans-
fection of a miR-21 precursor resulted in less PDCD4 and more produc-
tion of IL-10 after LPS stimulation, compared to controls. Thus miR-21
may inhibit the actions of PDCD4 on NF-κB activity and promote
the production of anti-inﬂammatory cytokines. Likewise, receptor-
interacting protein 140 (RIP140) is a nuclear protein believed to associ-
atewithNF-κB to aid in the transcription of pro-inﬂammatory cytokines
in macrophages [61]. Using an acute septic mouse model, Ho et al. [62]
identiﬁed that miR-33 targeted the 3′ UTR of RIP140 mRNA. They
observed that the transfection of miR-33 in RAW264.7 macrophages
resulted in the decrease in RIP140 mRNA, TNFα and IL-1βmRNA levels
after LPS stimulation.
Furthermore, Sweeny et al. [63] has reported that levels of Ppargc1a
are dysregulated in TLR2−/− and TLR4−/− mice infected with
Staphylococcus aureus. Ppargc1a, a member of PPAR-gamma coactivator
(PGC) family of transcriptional co-activators, is involved in the biogenesis
ofmitochondria and is believed to be stimulatedwhen there is damage to
the mitochondria during sepsis [64]. The authors observed that when a
miR-202-3p mimic was transfected into AML12 hepatocyte cells, levels
of Ppargc1a mRNA were reduced. In silico analyses of the 3‘UTR of
Ppargc1amRNA revealed binding sites for miR-202-3p, conﬁrming that
the activity of miR-202-3p is inversely related to Ppargc1a [63].
Activated protein C (aPC), an endogenous protein in the liver, is
known to decrease inﬂammation and reduce thrombosis [65]. The
administration of activated protein C (aPC) has been shown to im-
prove mortality in sepsis patients by modulating hepatic sinusoidal
vasoregulation and restoring hepatic oxygenation [66]. Moore and col-
leagues [67] have demonstrated that the actions of aPC are due to
changes in the miRNA expression during sepsis shock. Using the CLP
model inmale Sprague–Dawley rats, they reported an increase in levels
of miR-182, miR-199a-5p, miR-203, miR-211, miR-222, andmiR-29b in
hepatic tissue. They concluded that these microRNAs may be responsi-
ble for the formation of focal adhesions in hepatic tissue through the
aPC pathway. Another study by Wang et al. [68] examined the expres-
sion of miR-155 in LPS-induced sepsis in the liver of female BALB/c
mice. Some mice were pretreated with Dexamethasone (DMX), an
anti-inﬂammatory glucocorticoid, before LPS was administered intra-
peritoneally. Analysis of liver tissue of the two groups of mice revealed
that levels of miR-155 were upregulated 70-fold in LPS-treated mice
compared to those pretreated with DMX. Moreover, the DMX group
also displayed a decrease in pro-inﬂammatory cytokines TNFα and
IL-6 compared to the LPS group. Indeed,miR-155 has been found to tar-
get FADD and Ripk1 transcripts and indirectly promote translation of
TNFα [58]. The effects of miRNAs on inﬂammatory response mediators
are summarized in Table 2.s.
Effects Reference
4 Inhibit the activation of NF-κB [60]
0 Reduce the production of TNFα and IL-1β [62]
Inhibit PGC family –mediated biogenesis of mitochondria during
sepsis
[63]
Inhibit formation of focal adhesions in hepatic tissue [67]
Promote translation of TNFα [58]
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Sepsis can cause multiple organ dysfunction in the liver, kidney,
lungs and heart. Themechanisms underlying the clinical manifestations
and pathology of sepsis are complex. However, the prospect of miRNAs
being used as an indicator of the pathology of a speciﬁc condition is
promising, which may provide rapid diagnosis and conﬁrmation of in-
fection in sepsis patients.While numerousmiRNAs have been identiﬁed
to regulate the inﬂammatory response as reviewed here, whether these
intracellular miRNAs have therapeutic potential for the treatment of
sepsis remains largely unexplored. In addition, the role of the miRNAs,
albeit been conﬁrmed as critical regulators of the TLR- NF-κB pathway,
have not been studied extensively in sepsis models. Furthermore, all
therapeutic interventions aimed at speciﬁc mediators/pathways to
dampen the inﬂammatory response in sepsis have failed to improve
the outcome [69,70]. Thus, it will be of great signiﬁcance to continue
examining the role of extracellular and intracellular miRNAs in sepsis,
because it will not only help us understand the complex nature of sepsis
but also provide new insights for efﬁcient therapies.
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